PEPTIDES IN 2 — THYMOSIN ALPHA-1
World Peptide Foundation · Immune Defense & Inflammation · Collection episode 01

Thymosin alpha-1 opens our immune defense and inflammation collection. Immune health depends on coordinated responses.

In nineteen seventy-seven, Allan Goldstein and colleagues reported the isolation and sequence of this twenty-eight-amino-acid peptide from calf thymus. Its synthetic counterpart has the same amino acid sequence.

Laboratory studies examine how it influences dendritic cells, which help present information to T cells. This connects rapid innate defenses with targeted adaptive responses. Changes in an immune marker are not automatically clinical benefits.

That distinction matters in sepsis, where a dangerous response to infection can damage organs.

The TESTS trial enrolled eleven hundred six adults at twenty-two centers in China. Participants received thymosin alpha-1 or placebo alongside standard care.

Among the one thousand eighty-nine participants analyzed, twenty-eight-day mortality was twenty-three point four percent with the peptide and twenty-four point one percent with placebo. The corrected report found no clear mortality benefit. Its confidence interval included possible benefit and harm.

These findings describe a specific treatment strategy in adults with sepsis. They do not settle every question about thymosin alpha-1 or demonstrate an immune-boosting benefit in healthy people. Similar reported safety outcomes do not establish long-term safety. In the United States, it is not an FDA-approved medicine.

Connect immune biology to a defined disease, a measured outcome, and the strength of the human evidence.

World Peptide Foundation. Peptides in 2. Every experience matters.
